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Introduction. Measles continues to be a major public health issue 
worldwide, with high morbidity and mortality rates. The disease 
remains endemic in 14 European countries, including Italy where, 
from 2013 to 2016, over 5,000 cases have been reported. In 2017, 
many Italian regions, including Sicily, have reported many cases 
of measles. In this study, we described the latest measles outbreak 
in the city of Messina, from 1st February to 31st August 2017.
Methods. We considered all reported measles cases that came 
to the “Public Health, Epidemiology and Preventive Medicine” 
Operative Unit of the Messina Provincial Health Agency Preven-
tion Department, which receives all reported cases of measles in 
the Messina province.
Results. From 1st February to 31st August 2017, a total of 59 mea-
sles cases were reported, of which 44 were confirmed, nine were 
classified as possible, four were probable and two cases were 
discarded. Of the 57 possible, probable and confirmed cases, 
31 (54%) were males and 26 (46%) were females. Moreover, 54 
(95%) had not been previously vaccinated while the remaining 
cases had documented evidence of one (two cases) or two doses 
(one case). Genotype B3 was identified in 39/44 cases (88,6%) by 
the regional reference laboratory in Palermo.
Conclusions. Despite the development of an effective vaccination, 
unfortunately measles continues to threaten the lives of millions 
of children worldwide each year. The suboptimal immunization 
level in Italy has led to an increase in the transmission of measles 
with detrimental effects on both public health and ongoing mea-
sles elimination efforts.
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Introduction
Measles continues to be a major public health issue caus-
ing substantial outbreaks worldwide, with high morbid-
ity and mortality rates. In 2015, there were 134,200 
measles deaths globally – about 367 deaths every day or 
15 deaths every hour –. In the same year, approximately 
85% of children worldwide received primary vaccines 
before they are a year old (79% in 2000). Thanks to vac-
cinations, from 2000 to 2015, the incidence of measles 
in the world declined by 75%, from 146 to 36 cases per 
million inhabitants. However, the goal was to reduce, by 
2015, the mortality of 95% but this goal has not been 
achieved [1].
Since the beginning of 2017 and up to 10 September, 
the Italian Ministry of Health has reported 4,487 cases 
of measles and three deaths [2]. In this period, measles 
outbreaks have also been reported in other European 
countries, such as in Romania, which reported over 
7,000 cases and 31 deaths from January 2016 to June 
2017, most of them in small children [3]. In Romania, 
more than half of the cases occurred in children under 
five years of age, among unvaccinated or incompletely 
vaccinated individuals; in Italy, the majority of cases 
occurred among unvaccinated adolescents and young 
adults. This can be explained by the fact that Romania 
had very high levels of vaccine uptake (>  95%) up to 
2010, so many adults are protected; on the contrary, in 
Italy, the suboptimal vaccination coverage (< 95%), in 
particular among young adults born in the 1990s and 
2000s, has determined that these were more vulnerable 
and therefore were more affected by measles [4].
Eliminating measles and rubella is one of the top immu-
nization priorities of the European region, as outlined in 
the European Vaccine Action Plan 2015-2020, by defin-
ing priority action areas, indicators and targets, taking 
into account the specific needs and challenges of Mem-
ber States in the European Region [5]. 
Today, in the WHO European Region, 42 of 53 countries 
have interrupted endemic transmission of measles [6]. In 
Italy, measles has been reported since 1934 and an im-
proved surveillance system was introduced in 2007 [7]. 
From the 1970s to the end of the 1990s, measles showed 
the typical cyclical trend with very high epidemic peaks. 
With the increase in vaccine cover since the beginning of 
the 2000s, the extent of the spikes has decreased consid-
erably, and since 1997 the epidemic period has length-
ened. However, from 2013 to 2016, over 5,000 cases 
of measles have been reported. In January 2017, there 
was an increase in measles cases compared to previous 
months and January 2016  [8]. From the beginning of 
2017, a measles outbreak occurred in Messina (a city in 
eastern Sicily) and the surrounding areas. This outbreak 
was part of the wider epidemic in Italy that started in 
January 2017 and affected 20 of the 21 Italian adminis-
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trative regions [9]. Most cases occurred in Piedmont and 
Lombardy (northern Italy), Tuscany, Lazio and Abruzzo 
(central Italy) and Sicily (southern Italy). From January 
to the beginning of September 2017, Lazio region re-
ported the highest number of cases (n = 1589); Sicily, 
with 257 reported cases, is the sixth Italian region for 
number of cases. Measles outbreaks involved family, 
school and nosocomial spheres [10]. 
Even though it is a vaccine-preventable disease, measles 
vaccination coverage is suboptimal in Italy and especial-
ly in Sicily, with 87.3% and 81.1%, respectively, about 
the first dose for those born in 2014 [7]. Smaller cover-
age was reached for the second dose: 82.2% in Italy and 
64,7% in Sicily for those born in 2010 [11]. As a result, 
the pockets of vulnerable populations have increased. 
There is an even lower vaccine coverage about MMR 
vaccine in the city of Messina: 73% about the first dose 
for those born in 2014 and 45.4% about the first dose 
for those born in 2010 (data collected from the vaccine 
center in Messina, Department of Prevention Sanitary 
Provincial Hospital, Messina, Italy). As a result of the 
high transmissibility of the measles virus, the herd im-
munity threshold is very high, and consequently very 
high coverage (≥  95%) is necessary to interrupt virus 
transmission.
The aim of this study was to describe the measles out-
break that affected the city of Messina this year, to con-
duct a complete and rapid characterization of wild-type 
measles virus strains circulating and to implement ap-
propriate control measures to limit the spread of cases.
Methods 
We analysed the measles outbreak of Messina that oc-
curred from the 1st February to the 31st August 2017. 
We considered all measles cases reported to the “Pub-
lic Health, Epidemiology and Preventive Medicine” 
(SPEM) Operative Unit of the Messina Provincial 
Health Agency Prevention Department, which covers all 
measles cases in the Messina province. 
The measles case definition used during this outbreak 
was based on the European Commission case defini-
tion [12].
Measles cases were defined as possible, probable or 
confirmed, depending on clinical, epidemiological and 
laboratory criteria. A possible case was any person who 
met clinical criteria, i.e., fever, maculopapular rash and 
cough/coryza/conjunctivitis; a probable case was any 
person who met clinical criteria and had an epidemio-
logical link to a confirmed case; a confirmed case was 
any possible case with laboratory evidence of infection 
with the measles virus, i.e., detection of viral RNA in a 
biological sample and/or a positive IgM result in serum, 
under the indications of the National Plan of Elimina-
tion of Measles and Congenital Rubella [13]. Following 
the WHO criteria, cases were discarded when clinical, 
epidemiological or laboratory criteria were not met, tak-
ing into account vaccination history and risk of measles 
infection in the community or abroad [14].
Immediately after the notification, our Public Health 
team started an epidemiological investigation to under-
stand the retrospective identification of each reported 
case. Then, the case was included in the digital platform 
“Integrated measles and rubella surveillance” and was 
notified to health authorities. 
Tests for confirmation included: specific IgM antibodies 
detection by enzyme-linked immunosorbent (ELISA) 
assay from a capillary or venous blood sample and a 
sample of saliva collected between 4 and 28 days after 
the appearance of skin rash (this test was conducted by 
local laboratories of Messina city); molecular detection 
and genetic characterization of Morbillivirus (MV) by 
PCR assay on urine and/or oral fluid samples within 3 
days of the appearance of the exanthema and no later 
than 7 days (carried out by the regional reference labora-
tory in Palermo, Sicily).
Total RNA was extracted using QIAmp Viral RNA Mini 
Kit (Qiagen) for saliva samples and RNeasy mini Kit 
(Qiagen) for urine samples, as per the manufacturer’s 
protocols. Nucleic acid was tested by RT-PCR using a 
hemi-nested protocol directed to a highly conserved part 
of the MV RNA, which is located on the N gene (the 
carboxyl terminus of the nucleoprotein, N-450). 
Kit SuperScript One-Step RT-PCR kit with Platinum 
Taq (Invitrogen) was used for RT-PCR reaction. The 
sequences were genotyped by comparing the fragment 
coding for N-450 with that one of the WHO reference 
strains.
Results
From the 1st February to the 31st August 2017, 59 mea-
sles cases were notified in Messina, Sicily. 44 cases were 
laboratory-confirmed, nine were classified as possible, 
four were probable and two cases were discarded. 
The earliest case was reported on 2nd February, although 
the symptoms began at the end of January. Of the 57 
possible, probable and confirmed cases, 31 (54%) were 
males and 26 (46%) were females. Concerning the age, 
the most involved groups were 15-39 years (37%), chil-
dren between one and four years were 20 (35%); only 2 
cases occurred in children under one year. The percent-
age of all age groups are shown in Figure 1. Two of these 
cases were doctors and acquired measles in a healthcare 
setting. 
We defined a cluster as having a minimum of three peo-
ple with measles, for whom an epidemiological link to 
an identified index case, either directly or by secondary 
infection, was established. We recorded seven clusters, 
two clusters in Messina and the others in the rest of the 
province. The largest cluster involved 7  children who 
participated in a birthday party of a child with measles 
at the incubation stage; the other clusters were familiar 
clusters and involved 4 or 5 people maximum. In a fam-
ily cluster of Messina city our Public Health team has 
given measles-mumps-rubella (MMR) vaccine to two 
close contacts within 72 hours of exposure. 
M.A. PALAMARA ET AL.
E10
Of the 57 cases, 54 (95%) had not been previously vac-
cinated while the remaining cases had documented evi-
dence of one (two cases) or two doses (one case). Among 
the unvaccinated cases, three were infants under a year 
old and thus too young to be vaccinated; the remaining 
cases were in adolescents and adults.
Considering the trend of reported cases (Fig. 2), the peak 
was reached in April with 17 reported cases. 
In addition, 37 subjects (65%) were hospitalized; of 
which two infants (5%) were less than a year old, 11 
(30%) were between one and four years, five (13%) 
were 5-14 years old, 18 (49%) were 15-39 and one (3%) 
was more than 39 years of age. Of the total cases, nine 
subjects (16%) had at least one complication; diarrhea 
was the most frequent complication (n = 5), followed by 
kerato-conjunctivitis (n = 4), pneumonia (n = 2), stoma-
titis (n = 2), convulsion (n = 1) and otitis (n = 1) (Fig. 3). 
More complications were present simultaneously in the 
same subject.
Finally, genotype B3 was identified in 39 cases (88.6%) 
by the regional reference laboratory in Palermo; the oth-
er 5 confirmed cases remained not-typed.
Discussion and conclusions
Despite the development of an effective vaccination, 
measles unfortunately continues to threaten the lives of 
millions of children worldwide each year. Indeed, im-
munity gaps persist and the accumulation of measles-
susceptible population pockets in the context of an in-
creasing number of outbreaks in European countries 
Fig. 1. Percentage of measles cases.
Fig. 2. Monthly notification trend of outbreak.
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since 2016 could have contributed to this outbreak in our 
country [15, 16].
The decreased uptake of the measles-mumps-rubella 
(MMR) vaccine in Italy in recent years is also the re-
sult of vaccine hesitancy [17]. The immunization level 
in Italy for MMR is suboptimal with 87% of vaccination 
coverage rate for the first dose carried out by those born 
in 2014 and 79% for the second dose carried out by born 
in 2000 [7]. In Messina city, immunization level is very 
low with 73% of vaccination coverage rate for the first 
dose carried out by born in 2014 and 64% for the second 
dose carried out by born in 2000 (Department of Preven-
tion Sanitary Provincial Hospital, Messina, Italy). This 
situation has led to an increase in the transmission of 
measles with detrimental effects on both Public Health 
and ongoing measles elimination efforts.
Although the collective picture for European countries 
in 2016 reflects that the most affected age groups in Ro-
mania were infants and young children, more than 50% 
of cases in Italy and 45% of cases in the United King-
dom were ≥ 20 years of age. On the other hand, a high 
number of infections continues to be observed in unvac-
cinated one to four year olds in several countries across 
Europe [3]. 
From January 2009 to May 2010, 522 cases of measles 
occurred in Catania, Sicily, and all but one patients had 
not been vaccinated. This outbreak has shown that the 
practice of immunization was and continues to be inad-
equate in Sicily [18]. 
In our outbreak, all reported suspected measles cases 
were investigated and control measures were promptly 
implemented in order to contain transmission. Our pub-
lic health team undertook extensive contact tracing for 
all measles cases. Furthermore, surveillance and control 
measures included the immediate isolation of suspect-
ed cases and administration of measles-mumps-rubella 
(MMR) vaccine. Epidemiological investigations were 
complemented with broader Public Health measures that 
included raising public awareness about the importance 
of vaccinations, especially in children < 18 years and in 
healthcare workers, according to the National Vaccine 
Prevention Plan (PNPV 2017-19).
In our study, only two healthcare workers were involved, 
but a recent outbreak in Pisa (northern Italy) has involved 
many healthcare workers and their families [19]. 
Moreover, our data show all cases of B3 MV strains 
were spread across Italy and caused several autochtho-
nous cases and clusters. From November 2015 to April 
2016, an outbreak of measles B3 variant in the Roma/
Sinti population with transmission occurred in the no-
socomial setting. Therefore, in addition to healthcare 
workers, Roma also represent one of several undervacci-
nated population groups for whom stronger vaccination 
efforts are needed [20]. 
Genotype B3 was detected in some cases in the Milan 
(northern Italy) outbreak occurred from 1st March to 30th 
June 2017, even if the most common genotype detected 
was genotype D8  [21]. Genotype B3 was the same as 
the genotype detected in other outbreaks in Europe in 
2017, e.g., in Romania, Belgium, Portugal and the Unit-
ed Kingdom [22-25]. 
It is also important to remember that, for the most part, 
hospitalised patients was in the 15-39 age group. This re-
sult confirms that at most advanced age there is a higher 
hospitalization rate [26]. Moreover, we recorded 16% of 
complications, which were largely diarrhea, pneumonia 
and kerato-conjunctivitis, according to Italian cases (as 
detailed in the Measles in Italy weekly bulletin); how-
ever, measles can cause more serious complications and 
sometimes death. Not long ago, a case of fulminant sub-
acute sclerosing panencephalitis has occurred, which led 
to the death of a five-year-old Italian child  [27]. From 
January to end August 2017, in Italy, three deaths due to 
respiratory insufficiency occurred among children aged 
16 months, 6 years and 9 years respectively. All were un-
vaccinated and one child was immunocompromised due 
Fig. 3. Complications.
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to ongoing chemotherapy for a malignancy [9]. In Sep-
tember 2017, the fourth death for measles was recorded: 
a Sicilian 42-year-old man that was not vaccinated and 
immunocompromised [10]. 
The only positive side has been that the outbreak made 
physicians more aware of the measles diagnosis and sub-
sequent cases were quickly reported. So the problem of 
underreporting that has existed for many years, at least 
as far as measles is concerned, has been slightly reduced. 
Considering the current low coverage of the eligible 
population of Messina, an Extraordinary Plan for the Im-
provement of Vaccine Coverage for MMR was launched 
in accordance with the objectives set by the National 
Vaccine Prevention Plan (PNPV 2017-2019) and the Re-
gional Prevention Plan [28]. This plan involves pediatri-
cians, general practitioners and other healthcare profes-
sionals in Sicily; it aims to make vaccinations more ac-
cessible and to raise awareness in order to overcome the 
widespread distrust of those against vaccinations.
As already stated by the WHO, the elimination of mea-
sles and rubella will depend largely on obtaining politi-
cal commitment, achieving high coverage, closing im-
munity gaps and implementing high quality, case-based 
surveillance.
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